Thrombocytopenia News and Research

RSS

Thrombocytopenia is a condition in which there is a lower-than-normal number of platelets in the blood. It may result in easy bruising and excessive bleeding from wounds or bleeding in mucous membranes and other tissues.

Immune checkpoint inhibitors can trigger rare immune thrombocytopenia in cancer patients

Researchers led by investigators at Mass General Brigham have published valuable information about a rare but serious complication of anti-cancer immunotherapy, providing the first large-scale description of its risk factors and clinical course, and underscoring the importance of early diagnosis and treatment.

12 Dec 2025

Research ushers in a new era of hope for patients with primary immune thrombocytopenia

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia (ITP), an autoimmune disorder that can cause life-threatening bleeding, were able to maintain safe platelet counts without serious bleeding episodes for at least one year.

9 Dec 2025

EULAR develops new disease activity score for antiphospholipid syndrome

EULAR - The European Alliance of Associations for Rheumatology - has developed a new disease activity score that quantifies the level of disease activity in people with antiphospholipid syndrome (APS).

19 Nov 2025

Breakthrough in FcγRI inhibition opens path to safer autoimmune therapies

An international research group directed by UMC Utrecht have developed and characterized two first-in-class antibodies that specifically block the high-affinity IgG receptor FcγRI.

19 Nov 2025

Acquired immune thrombotic thrombocytopenic purpura develops after vaccination with CoronaVac

Researchers from the Second Affiliated Hospital of Nanjing Medical University, et al. have published a case report entitled "Acquired immune thrombotic thrombocytopenic purpura (TTP) associated with inactivated COVID-19 vaccine CoronaVac". This report was published in Frontiers of Medicine, Volume 18, Issue 4, 2024.

17 Nov 2025

Understanding thrombocytopenia in patients with portal hypertension and chronic liver disease

Chronic liver disease (CLD) and its advanced stage, cirrhosis, represent a significant global health burden, with portal hypertension (PH) being a primary driver of disease progression and decompensation.

12 Nov 2025

Assessing the risk of tick bites and effectiveness of protective measures in northeastern China

Announcing a new article publication for Zoonoses journal. In northeastern China, tick-borne diseases pose a major public health challenge, which is exacerbated by environmental and anthropogenic changes.

10 Nov 2025

Children face greater heart and inflammatory risks after COVID-19 infection than vaccination

The study is the largest of its kind in this population, and is published in The Lancet Child and Adolescent Health.

4 Nov 2025

New antibody-drug conjugate iza-bren may offer promising treatment option for EGFR-mutated NSCLC patients

A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrated encouraging safety and efficacy results in previously treated patients with EGFR-mutated non-small cell lung cancer (NSCLC), according to findings presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).

8 Sep 2025

Single antibody causes a rare but dangerous reaction to widely-used blood thinner

Researchers at McMaster University have discovered that a rare but dangerous reaction to a widely used blood thinner is caused by a single antibody – overturning decades of medical misunderstanding and opening the door to more precise ways of diagnosing and treating this medical complication.

3 Sep 2025

New study reveals unexpected role of red blood cells in clot formation

Red blood cells, long thought to be passive bystanders in the formation of blood clots, actually play an active role in helping clots contract, according to a new study from researchers at the University of Pennsylvania.

6 Aug 2025

New study confirms cardiovascular safety of COVID-19 vaccines

The incidence of heart attacks and strokes was lower after COVID-19 vaccination than before or without vaccination, according to a new study involving nearly the whole adult population of England.

1 Aug 2025

New insights into tick immune response could help prevent deadly virus transmission

Severe Fever with Thrombocytopenia syndrome virus (SFTSV) is a severe haemorrhagic fever virus transmitted by tick to animal and humans. Discovered in 2009, the virus is found in South-East Asian countries and has a fatality rate of up to 40%.

22 Jul 2025

Lipoxygenase emerges as a promising antiviral agent against severe fever with thrombocytopenia syndrome

Severe fever with thrombocytopenia syndrome (SFTS) was reported in Asia, with a fatality rate that can reach as high as 50%.

18 Jul 2025

Teclistamab shows promising results in heavily pretreated multiple myeloma

Teclistamab-cqyv (Tecvayli) led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who would have been ineligible for the MajesTEC-1 trial, and identified a novel factor independently associated with outcomes.

12 Jul 2025

A comprehensive review of vaccine approaches for severe fever with thrombocytopenia syndrome

Announcing a new article publication for Zoonoses journal. Severe fever with thrombocytopenia syndrome (SFTS), caused by the tick-borne severe fever with thrombocytopenia syndrome virus (SFTSV), is a disease that is endemic to East Asia and has mortality rates reaching 30%.

6 May 2025

Why measles is back in the U.S. and what doctors must know now

Measles is making a troubling comeback in the U.S., driven by declining vaccination rates and rising vaccine hesitancy. Pediatric infectious disease experts provide clinical guidance to help healthcare providers recognize, manage, and prevent measles in today’s outbreak-prone environment.

14 Apr 2025

Novel ARPC1B mutation identified in a patient with recurrent eosinophilia

Immunodeficiency disorders linked to cytoskeleton defects are rare and complex, often presenting with diverse clinical features.

1 Apr 2025

WINREVAIR™ (sotatercept-csrk) reduced the risk of a composite of all-cause death, lung transplantation and hospitalization for pulmonary arterial hypertension (PAH) by 76% compared to placebo in the phase 3 ZENITH trial

Merck, known as MSD outside of the United States and Canada, today announced the first presentation of results from the Phase 3 ZENITH trial evaluating WINREVAIR™ (sotatercept-csrk) compared to placebo in adults with pulmonary arterial hypertension (PAH, Group 1 PH) WHO* functional class (FC) III or IV at high risk of mortality who were on maximum tolerated background PAH therapy. At a median follow-up of 10.6 months (range, 0.3-26.1), WINREVAIR reduced the relative risk of major morbidity and mortality events (the composite of all-cause death, lung transplantation and PAH worsening-related hospitalization of ≥24 hours) by 76% (HR=0.24 [95% CI, 0.13-0.43]; p<0.0001 [1-sided]) compared to placebo.